Earlier defibrotide initiation post-diagnosis of veno-occlusive disease/sinusoidal obstruction syndrome improves Day +100 survival following haematopoietic stem cell transplantation. Richardson PG et al. Br J Haematol. 2017 Apr 26. doi: 10.1111/bjh.14727. [Epub ahead of print]. Trends in vertebral augmentation for spinal fractures in myeloma patients: a 2002-2012 population-based study using a large national cancer registry. Chokshi FH et al. J Neurointerv Surg. 2017 Apr…
Bortezomib pharmacokinetics in tumor response and peripheral neuropathy in multiple myeloma patients receiving bortezomib-containing therapy. Lee SE et al. Anticancer Drugs. 2017 Apr 20. doi: 10.1097/CAD.0000000000000506. [Epub ahead of print]. Paraneoplastic acute disseminated encephalomyelitis associated with multiple myeloma. Law LY et al. Mult Scler Relat Disord. 2017 Apr;13:21-24. doi: 10.1016/j.msard.2017.01.013. Pharmacokinetics and safety of carfilzomib in patients with relapsed multiple myeloma and end-stage renal disease (ESRD):…
Benefit of continuous treatment for responders with newly diagnosed multiple myeloma in the randomized FIRST trial. Bahlis NJ et al. Leukemia. 2017 Apr 4. doi: 10.1038/leu.2017.111. [Epub ahead of print]. Lenalidomide, adriamycin, dexamethasone (RAD) for induction followed by stem-cell transplant in newly diagnosed myeloma. Knop S et al. Leukemia. 2017 Apr 25. doi: 10.1038/leu.2017.124. [Epub ahead of print]. Lenalidomide, Bortezomib, and Dexamethasone with Transplantation…
A study examining the number of visits people made to their GP before being diagnosed with cancer through accident and emergency (A&E) has shown that myeloma patients presenting via this route have the highest number of prior GP visits than any other cancer. Published recently in the British Journal Of General Practice, researchers from the Universities of…
The International Myeloma Working Group (IMWG) has published a consensus statement providing recommendations for the best use of 18-fluorodeoxyglucose (18F-FDG) PET/CT in the diagnosis and management of myeloma patients. Published in the Lancet Oncology, they consider this technique to be valuable not only in the initial work up for newly diagnosed myeloma patients but also…
This paper, written by the International Myeloma Working Group (IMWG), reviews the current evidence, and provides recommendations for the optimal use of 18F-FDG PET/CT in the diagnosis and management of multiple myeloma and related diseases, including smouldering myeloma and solitary plasmacytoma.
Update on the optimal use of bortezomib in the treatment of multiple myeloma. Mohan M et al. Cancer Manag Res. 2017 Mar 2;9:51-63. doi: 10.2147/CMAR.S105163. eCollection 2017. Multiple Myeloma: Diagnosis and Treatment. Michels TC et al. Am Fam Physician. 2017 Mar 15;95(6):373-383. Monoclonal antibody therapy in multiple myeloma. Touzeau C et al. Leukemia. 2017 Mar 10. doi: 10.1038/leu.2017.60. [Epub ahead of print]. Patients with myeloma need more time…
Reinforced cementoplasty using dedicated spindles in the management of unstable malignant lesions of the cervicotrochanteric region. Premat K et al. Eur Radiol. 2017 Mar 13. doi: 10.1007/s00330-017-4774-3. [Epub ahead of print]. Biosimilar Retacrit® (epoetin zeta) in the treatment of chemotherapy-induced symptomatic anemia in hematology and oncology in Germany (ORHEO) – non-interventional study. Losem C et al. Onco Targets Ther. 2017 Feb…
Neuropathy and efficacy of once weekly subcutaneous bortezomib in multiple myeloma and light chain (AL) amyloidosis. Sidana S et al. PLoS One. 2017 Mar 9;12(3):e0172996. doi: 10.1371/journal.pone.0172996. eCollection 2017. Late recurrence of autologous GvHD in a myeloma patient: a myth or diagnostic challenge? El-Jurdi N et al. Bone Marrow Transplant. 2017 Mar 20. doi: 10.1038/bmt.2017.20. [Epub ahead of print]. Long-term control of extensive refractory chronic…
Phase II study of dose-attenuated bortezomib, cyclophosphamide and dexamethasone (“VCD-Lite”) in very old or otherwise toxicity-vulnerable adults with newly diagnosed multiple myeloma. Tuchman SA et al. J Geriatr Oncol. 2017 Feb 27. pii: S1879-4068(17)30030-9. doi: 10.1016/j.jgo.2017.02.004. [Epub ahead of print]. Carfilzomib containing combinations as frontline therapy for multiple myeloma: a meta analysis of 13 trials. Sheng Z et al. Eur J Haematol. 2017…